Articles / Medicolegal Risks and the COVID-19 Vaccine Rollout
0 hours
These are activities that expand general practice knowledge, skills and attitudes, related to your scope of practice.
0 hours
These are activities that require reflection on feedback about your work.
0 hours
These are activities that use your work data to ensure quality results.
These are activities that expand general practice knowledge, skills and attitudes, related to your scope of practice.
These are activities that require reflection on feedback about your work.
These are activities that use your work data to ensure quality results.
This week’s experts:
Dr Penny Browne, GP; Senior Staff Specialist in General Practice, Hornsby Hospital, Sydney; Chief Medical Officer, Avant
Ms Georgie Maysom, Lawyer; Head of Research, Education and Advocacy, Avant
Drawn from the lecture interview with Dr Penny Browne and Ms Georgie Maysom on the Healthed Podcast, ‘Medicolegal Risks and the COVID-19 Vaccine Rollout’
– Ensure people presenting for the vaccine are eligible. This is more of a challenge when people who don’t usually come to your practice present for vaccination. Can ask for a health summary from usual doctor, or get them to complete a medical history questionnaire. Easiest solution is to get patient to complete an ‘eligibility declaration’ – downloadable from the Department of Health website.
‘
Obstructive Sleep Apnoea & Driving: The GP's Role
Non-Hormonal & Hormonal Options for Hot Flushes
Why is LDL Control Important?
Muscle Health in Chronic Disease: A Practical Guide for GPs
Strongly agree
Slightly agree
Slightly disagree
Strongly disagree
Listen to expert interviews.
Click to open in a new tab
Browse the latest articles from Healthed.
Once you confirm you’ve read this article you can complete a Patient Case Review to earn 0.5 hours CPD in the Reviewing Performance (RP) category.
Select ‘Confirm & learn‘ when you have read this article in its entirety and you will be taken to begin your Patient Case Review.
Menopause and MHT
Multiple sclerosis vs antibody disease
Using SGLT2 to reduce cardiovascular death in T2D
Peripheral arterial disease